Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | FABP3 | P05413 | 2/20 | 0.38 |
| ▸ | FABP4 | P15090 | 2/20 | 0.38 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.37 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.33 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.32 |
| ▸ | MYC | P01106 | 1/20 | 0.32 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.32 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.32 |
| ▸ | GCGR | P47871 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14404556 | 0.87 | EIF4A3 (0.37) | GABRA1GABRB2FABP3FABP4EIF4A3 | |
| SCHEMBL28217295 | 0.85 | GABRA1 (0.46) | GABRA1GABRB2FABP3FABP4FABP5 | |
| SCHEMBL12447347 | 0.82 | GCGR (0.36) | GABRA1GCGRGABRG2GABRB3HSP90AB1 | |
| SCHEMBL19658127 | 0.78 | TAAR1 (0.44) | GABRA1GABRB2GCGRGABRG2GABRB3 | |
| SCHEMBL31076106 | 0.78 | ADRB2 (0.36) | GABRA1GABRB2EIF4A3 | |
| SCHEMBL31075804 | 0.76 | EIF4A3 (0.34) | GABRA1GABRB2EIF4A3 | |
| SCHEMBL25138922 | 0.74 | GCGR (0.38) | GABRA1GCGRGABRG2GABRB3 | |
| SCHEMBL12248246 | 0.74 | GABRA1 (0.50) | GABRA1GABRB2FABP3FABP4FABP5 | |
| SCHEMBL25736473 | 0.73 | — | — | |
| SCHEMBL22657432 | 0.72 | EIF4A3 (0.36) | GABRA1GABRB2EIF4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210277007-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2021-09-09 | — | — | US | disclosed |
| US-10919902-B2 | Hetero-halo inhibitors of histone deacetylase | ALKERMES, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| US-20200247814-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247814-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | HDAC2, HDAC1, HDAC6 | GABRA1 379/4885GABRB2 394/4885FABP3 3593/4885 |
| US-10919902-B2 | Hetero-halo inhibitors of histone deacetylase | HDAC2, HDAC1, HDAC6 | GABRA1 379/4885GABRB2 394/4885FABP3 3593/4885 |
| US-20210277007-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | HDAC2, HDAC1, HDAC6 | GABRA1 379/4885GABRB2 394/4885FABP3 3593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.